Scholarlink

<p>We describe the design of the first non-pharmacological Parkinson’s disease prevention trials worldwide: the randomised ‘Slow-SPEED’ trials. Three trials examine the feasibility and preliminary efficacy of a gamified, remotely administered exercise intervention vs. active control over 18–36 months in complementary prodromal subgroups: iRBD(<i>n</i> = 110; Netherlands), hyposmia(<i>n</i> = 110; United Kingdom) or LRRK2/GBA1 mutation carriers(<i>n</i> = 600; United States). These trials will provide unique insights for large-scale Parkinson’s prevention studies. Protocols are registered at ClinicalTrials.gov(NCT06193252[1-5-2024];NCT06600438[9-19-2024];NCT06993142[5-28-2025]).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月14日

查看全文
  • Thomas H. Oosterhof,
  • Eleanor Mitchell,
  • Alberto Ascherio,
  • Stella Aslibekyan,
  • Viktoria Azoidou,
  • Kara Beasley,
  • Yoav Ben-Shlomo,
  • Eline Bunnik,
  • Camille Carroll,
  • Lana Chahine,
  • Daniel Corcos,
  • Jules M. Janssen Daalen,
  • Karin D. van Dijk,
  • Bauke W. Dijkstra,
  • Lisanne Dommershuijsen,
  • Ray Dorsey,
  • Luc J. W. Evers,
  • Rick C. Helmich,
  • Martin Johansson,
  • Lucy Norcliffe-Kaufmann,
  • Jessi Keavney,
  • Christine Klein,
  • Matthew J. Kmiecik,
  • Thomas Kustermann,
  • Eric A. Macklin,
  • Kenneth Marek,
  • Sanne K. Meles,
  • Sebastiaan Overeem,
  • Carl M. Philpott,
  • Angelique Pijpers,
  • Ronald B. Postuma,
  • Helen M. Rowbotham,
  • Sabine Schootemeijer,
  • Michael A. Schwarzschild,
  • Tanya Simuni,
  • Michael Sommerauer,
  • Ambra Stefani,
  • Kenan Steidel,
  • Marcel Verbeek,
  • Rick van der Vliet,
  • Nienke M. de Vries,
  • Bart van de Warrenburg,
  • Richard K. Wyse,
  • Bastiaan R. Bloem,
  • Ruth B. Schneider,
  • Alastair J. Noyce,
  • Sirwan K. L. Darweesh

摘要

We describe the design of the first non-pharmacological Parkinson’s disease prevention trials worldwide: the randomised ‘Slow-SPEED’ trials. Three trials examine the feasibility and preliminary efficacy of a gamified, remotely administered exercise intervention vs. active control over 18–36 months in complementary prodromal subgroups: iRBD(n = 110; Netherlands), hyposmia(n = 110; United Kingdom) or LRRK2/GBA1 mutation carriers(n = 600; United States). These trials will provide unique insights for large-scale Parkinson’s prevention studies. Protocols are registered at ClinicalTrials.gov(NCT06193252[1-5-2024];NCT06600438[9-19-2024];NCT06993142[5-28-2025]).